<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="828">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00099710</url>
  </required_header>
  <id_info>
    <org_study_id>IA0065</org_study_id>
    <nct_id>NCT00099710</nct_id>
  </id_info>
  <brief_title>Curcumin in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>A Phase II, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of Two Doses of Curcumin C3 Complex Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Douglas French Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute for the Study of Aging (ISOA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Aging (NIA)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and tolerability of curcumin, and to&#xD;
      determine its effect on patients with mild to moderate Alzheimer's Disease (AD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Curcumin, a yellow substance found in the spice Turmeric, has antioxidant, non-steroidal&#xD;
      anti-inflammatory (NSAID), and cholesterol-lowering properties, all of which make it a good&#xD;
      candidate in the prevention and treatment of AD. The study will examine the safety and&#xD;
      tolerability of 2 different doses of curcumin C3 complex. Blood and cerebrospinal fluid (CSF)&#xD;
      tests will be used to examine how the curcumin is absorbed in the body, and whether it has an&#xD;
      effect on inflammation, oxidative damage, and cholesterol levels. Participants will also be&#xD;
      tested to determine the potential effect of curcumin on cognition, behavior, and daily&#xD;
      function in patients with mild to moderate AD.&#xD;
&#xD;
      Participants will be randomly assigned to receive one of two doses of curcumin, or a placebo,&#xD;
      for the initial 6 months of the trial. For the final 6 months, those receiving a placebo will&#xD;
      be switched to one of the two doses of the drug. The 33 participants will make 7 visits to&#xD;
      the study site over a 12-month period. These visits may include a physical and neurological&#xD;
      examination, routine laboratory tests, lumbar puncture, and neuropsychological (mood and&#xD;
      memory) evaluations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Side effect checklist</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative damage</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation/gliosis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A-beta levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tau levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma cholesterol, LDL and HDL; ApoE</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma curcumin and metabolites</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive and behavioral measures</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Alzheimer's Disease</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcumin C3 Complex</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female at least 50 years old&#xD;
&#xD;
          -  Diagnosis of probable AD&#xD;
&#xD;
          -  No history of significant psychiatric or non-AD neurological disease&#xD;
&#xD;
          -  Proficient in English to be able to perform cognitive testing&#xD;
&#xD;
          -  Caregiver available to monitor and administer medication and to accompany patient to&#xD;
             every clinical visit&#xD;
&#xD;
          -  On stable doses of cholinesterase inhibitors and memantine (Alzheimer's medications)&#xD;
             for 3 months prior to enrollment&#xD;
&#xD;
          -  On stable doses of all other allowed medications for at least one month prior to&#xD;
             starting the study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or recent major psychiatric illness (i.e. bipolar disorder, schizophrenia)&#xD;
&#xD;
          -  Significant, uncontrolled systemic illness (i.e. chronic renal failure, chronic liver&#xD;
             disease, poorly controlled diabetes, or poorly controlled congestive heart failure)&#xD;
&#xD;
          -  Recent history of gastrointestinal bleeding or ulceration&#xD;
&#xD;
          -  Alcoholism or substance abuse within the past year&#xD;
&#xD;
          -  Familial, autosomal dominant Alzheimer's disease due to a mutation in a known gene&#xD;
             (Presenilin-1, Presenilin-2, or Amyloid Precursor Protein)&#xD;
&#xD;
          -  NSAIDs (e.g. ibuprofen, naproxen, etc.) taken on a regular basis (more than 3 times&#xD;
             per week)&#xD;
&#xD;
          -  Aspirin at doses more than 325 mg per day&#xD;
&#xD;
          -  Coumadin, heparin, other anticoagulants&#xD;
&#xD;
          -  Antioxidants or other supplements including gingko biloba, coenzyme Q10, alpha-lipoic&#xD;
             acid&#xD;
&#xD;
          -  Vitamin E at doses more than 2,000 IU per day&#xD;
&#xD;
          -  Vitamin C at doses more than 500 mg per day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Ringman, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chandra V, Pandav R, Dodge HH, Johnston JM, Belle SH, DeKosky ST, Ganguli M. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology. 2001 Sep 25;57(6):985-9.</citation>
    <PMID>11571321</PMID>
  </reference>
  <reference>
    <citation>Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001 Nov 1;21(21):8370-7.</citation>
    <PMID>11606625</PMID>
  </reference>
  <reference>
    <citation>Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005 Feb 18;280(7):5892-901. Epub 2004 Dec 7.</citation>
    <PMID>15590663</PMID>
  </reference>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 17, 2004</study_first_submitted>
  <study_first_submitted_qc>December 17, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2004</study_first_posted>
  <last_update_submitted>December 2, 2009</last_update_submitted>
  <last_update_submitted_qc>December 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2009</last_update_posted>
  <keyword>Curcumin</keyword>
  <keyword>Turmeric</keyword>
  <keyword>Curry</keyword>
  <keyword>NSAID</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>anti-oxidant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

